Print This Page
 

 

(Between 9am-6pm EST)

 

The MMRC: Advancing Promising Treatments for People with Multiple Myeloma


The Multiple Myeloma Research Consortium (MMRC) has been charged with unifying the collaboration and integration of academia and industry, focusing on developing the most avant-garde, progressive, and promising treatments for people living with multiple myeloma. Founded in 2004, the MMRC was the only program willing to explore a new approach, bringing together leading members of academic centers to solely concentrate on Phase I and Phase II clinical trials. Today, the MMRC has 16 member Institutions that are fully integrated and driven by highly defined metrics mandating accountability and strongly promoting team science.

The MMRC Steering Committee

The MMRC’s research efforts are selected and overseen by a dynamic team of experts in the field of multiple myeloma, including representation from world-renowned MMRC Member Institutions, as well as key leadership from the MMRF. This multidisciplinary team, with expertise in the fields of multiple myeloma research, clinical care, and executive leadership, provides both strategic direction and scientific oversight to the Consortium.

Kenneth Anderson, MD - Chair

Chief, Division of Hematologic Neoplasia
Director, Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute

Dr. Anderson graduated from Johns Hopkins Medical School. He trained in internal medicine at Johns Hopkins Hospital and completed hematology, medical oncology, and tumor immunology training at the Dana-Farber Cancer Institute. Dr. Anderson is the Kraft Family Professor of Medicine at Harvard Medical School and serves as Chief of the Division of Hematologic Neoplasia, Director of the Jerome Lipper Multiple Myeloma Center, and Vice Chair of the Joint Program in Transfusion Medicine at the Dana-Farber Cancer Institute. He received the Waldenstrom's Award in 2003 for his translational research directed to the development of novel therapeutics targeting the myeloma cell in its microenvironment. He serves as Chair of the National Comprehensive Cancer Network's Multiple Myeloma Clinical Practice Guidelines Committee, the Board of Directors and Chairman of the Scientific Advisors of the Multiple Myeloma Research Foundation, and a Doris Duke Distinguished Clinical Research Scientist.

 

Andrzej Jakubowiak, MD, PhD

University of Chicago

Andrzej Jakubowiak received both his medical and doctoral degrees from the Medical Academy in Pozan, Poland. Prior to joining the faculty of the University of Michigan in 2000, Dr. Jakubowiak completed a fellowship in hematology/oncology from Memorial Sloan-Kettering Cancer Center in New York. His clinical interests are in the treatment of multiple myeloma and other hematological malignancies including Hodgkin’s and non-Hodgkin’s lymphoma, and acute/chronic leukemia. Dr. Jakubowiak’s research focuses on treatment protocols for multiple myeloma and lymphoma.

 

Sagar Lonial, MD

Professor
Vice Chair of Clinical Affairs
Department of Hematology and Medical Oncology
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Dr. Lonial is a Professor in the Department of Hematology and Medical Oncology at the Winship Cancer Institute of Emory University, where he is also Vice Chair of Clinical Affairs for the department, and Director of the Translational Research B-Cell Malignancy Program. He earned his medical degree from the University of Louisville School of Medicine in Kentucky. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in Hematology/Oncology at Emory University School of Medicine in Atlanta, Georgia. Dr Lonial’s research focuses on combination therapy in B-cell malignancies in myeloma. He is a trained bone marrow transplant physician with an interest in molecular therapy for lymphoma and myeloma. His clinical interests include evaluating the combination of new molecular-targeted agents for B-cell cancers, as well as methods to enhance immunity following allogeneic or autologous stem cell transplant. Dr Lonial is a member of several local committees, as well as a member of several committees for the American Society of Hematology. He is also involved in numerous professional organizations including the American Society of Clinical Oncology and the American Society for Blood and Marrow Transplantation. In addition, he serves on the editorial board of the American Journal of Clinical Oncology and as an invited or ad hoc reviewer for several publications, including Blood, Journal of Clinical Oncology, Haematologica, Clinical Cancer Research, Leukemia, and others. Dr Lonial has authored or coauthored numerous publications and abstracts and has given several presentations, locally, nationally, and internationally.

 

A Network of Remarkable Resources

World-Renowned Academic Institutions

The MMRC is currently comprised of 16 world-renowned academic institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Ohio State University, Mount Sinai School of Medicine, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University.

MMRC Tissue Bank

Integral to MMRC research and drug development efforts is the MMRC Tissue Bank, a cutting-edge resource that bridges laboratory and clinical research conducted by the MMRC. The MMRC Tissue Bank also plays a vital role in the MMRC’s preclinical validation studies of novel and combination therapies, and in conducting basic science research to develop a greater understanding of the biology of multiple myeloma.

Cutting-edge Research Cores

The MMRC is currently conducting exciting research efforts across 3 highly aligned research cores: genomics, validation, and clinical trials. These efforts truly span the spectrum of drug development, from the identification of new druggable targets, to the validation of novel and combination therapies, to advancing new compounds into Phase I and Phase II clinical trials.

Research and Drug Development Projects

Committed to bringing better, more effective new treatments to patients as quickly as possible, the MMRC is highly focused on spearheading Phase I and II clinical trials with associated correlative science studies. Since its inception, the MMRC has facilitated the launch of more than 30 clinical trials of novel compounds and combination approaches. The MMRC also conducts preclinical validation studies to identify and prioritize the most promising novel compounds and combination therapies, and conducts genomics studies to develop a greater understanding of the biology of multiple myeloma.